Tetracycline in uti
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have enough authoritative content to provide a comprehensive answer. Here's a synthesis:
Tetracycline in Urinary Tract Infection (UTI)
Mechanism of Action
Tetracyclines inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment.
Why Tetracycline Can Work in UTI — Despite "Resistance" on Susceptibility Testing
A key pharmacokinetic property makes tetracycline uniquely relevant in UTI:
Tetracycline is so heavily concentrated in the urine that it achieves levels that exceed even the elevated MICs of organisms like Pseudomonas aeruginosa, and can successfully treat P. aeruginosa cystitis — even when the organism tests as "resistant" in standard in vitro susceptibility panels.
This means that standard MIC-based susceptibility designations ("susceptible/resistant") are based on achievable blood/tissue levels. For UTI, urinary drug concentration is the relevant parameter, which can be far higher. — Goldman-Cecil Medicine
Tetracycline Derivatives: Current Clinical Role in UTI
| Agent | UTI Use |
|---|---|
| Tetracycline (classic) | Historically used; now largely replaced by doxycycline and other agents |
| Doxycycline | Not a first-line UTI agent; used for urethritis (Chlamydia trachomatis), atypical pathogens |
| Minocycline | Similar spectrum to doxycycline; not a standard UTI agent |
| Tigecycline | Should not be used for UTI — poor urinary concentrations |
| Eravacycline | Should not be used for UTI — poor urinary concentrations; failed to demonstrate non-inferiority in clinical trials |
| Omadacycline | Not indicated for UTI |
— Washington Manual of Medical Therapeutics
Specific Indications Where Tetracyclines Are Used in Urinary/Pelvic Infections
- Urethritis caused by Chlamydia trachomatis — doxycycline 100 mg PO BID × 7 days is standard therapy
- Complicated UTI where organism sensitivity is confirmed and alternatives are unavailable
- Pseudomonas aeruginosa cystitis — classic tetracycline (not derivatives) can be effective due to urinary concentration, despite in vitro "resistance"
Key Contraindications / Cautions
- Pregnancy: Tetracyclines are contraindicated (can cause tooth enamel discoloration and skeletal abnormalities in the fetus). For UTI in pregnancy, safer alternatives (nitrofurantoin, cephalosporins, amoxicillin) are preferred. — Goldman-Cecil Medicine / Brenner and Rector's The Kidney
- Children < 8 years: Risk of permanent tooth discoloration
- Renal impairment: Most tetracyclines (except doxycycline) accumulate and worsen azotemia — avoid in renal failure
- Esophageal ulceration: Oral tetracyclines must be taken upright with adequate fluid
- Drug interactions: Absorption significantly impaired by antacids (Al³⁺, Mg²⁺), calcium, iron, and other polyvalent cations — separate by ≥2 hours
First-Line UTI Agents (for context)
Tetracyclines are not standard first-line UTI agents. Current first-line options include nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin for uncomplicated cystitis; fluoroquinolones or beta-lactams for pyelonephritis.
Bottom line: Classic tetracycline achieves high urinary concentrations and was historically used for UTI, including against resistant organisms. However, newer tetracycline derivatives (tigecycline, eravacycline) are not suitable for UTI due to poor urinary penetration. Doxycycline is the primary tetracycline used today but mainly for urethritis/atypical coverage, not typical bacterial cystitis/pyelonephritis.
Malignant glaucoma atropin use
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Excellent — I now have comprehensive, authoritative content from two dedicated ophthalmology textbooks. Here is the full answer:
Atropine in Malignant Glaucoma (Aqueous Misdirection Syndrome)
What is Malignant Glaucoma?
Malignant glaucoma — also called aqueous misdirection syndrome — is a rare but serious condition characterized by:
- Posterior misdirection of aqueous humor into or behind the vitreous, due to anterior rotation of the ciliary body (ciliolenticular block)
- Aqueous accumulates in the vitreous → pushes the lens-iris diaphragm forward → secondary angle closure
- Classically occurs after incisional or laser surgery in eyes with small anterior segments (hyperopia, nanophthalmos, primary angle-closure glaucoma)
- May also occur spontaneously, or be precipitated by miotics
Key diagnostic signs:
- Diffusely shallow or flat anterior chamber
- Elevated IOP
- Patent peripheral iridectomy (PI) — this rules out pupillary block
- Absent iris bombé, absent choroidal detachment (on B-scan USS)
- Negative Seidel test
— Kanski's Clinical Ophthalmology; Wills Eye Manual
Why Atropine? — Mechanism
Atropine is a muscarinic antagonist (anticholinergic / cycloplegic-mydriatic). In malignant glaucoma it works by:
- Dilating the ciliary ring — relaxing the ciliary muscle reverses the anterior rotation of the ciliary processes
- Increasing the distance between the ciliary processes and the equator of the lens — this relieves ciliolenticular block
- Tightening the zonules → pulls the lens posteriorly back into its normal position
- Deepening the anterior chamber — restoring normal anterior aqueous flow
This is the opposite mechanism to miotics (pilocarpine), which worsen the condition by further contracting the ciliary muscle and tightening the ciliolenticular block. Miotics are absolutely contraindicated in malignant glaucoma.
— Kanski's Clinical Ophthalmology, p. 435; Wills Eye Manual, p. 624
Treatment Protocol
Step 1 — Medical therapy (first line):
| Drug | Dose | Purpose |
|---|---|---|
| Atropine 1% topical | q.i.d. | Cycloplegia, reverses ciliolenticular block |
| Phenylephrine 2.5–10% topical | q.i.d. | Mydriasis, synergistic posterior lens displacement |
| Acetazolamide (CAI) | 500 mg IV or 250 mg PO × 2 | Reduce aqueous production |
| Timolol 0.5% topical | daily or b.i.d. | Reduce aqueous production |
| Brimonidine/apraclonidine topical | b.i.d. | Reduce aqueous production |
| Mannitol 20% IV | 1–2 g/kg over 45 min | Vitreous shrinkage → posterior lens movement |
Mannitol is particularly useful if mydriatics are ineffective — it shrinks the vitreous gel and causes the lens to move posteriorly. — Kanski's
Step 2 — If attack is broken:
- Continue atropine 1% daily, indefinitely (maintenance) to prevent recurrence
- Perform PI in the contralateral eye if the angle is occludable
Step 3 — If medical therapy fails:
- Nd:YAG laser disruption of the anterior hyaloid face (and posterior capsule in pseudophakic/aphakic eyes)
- Pars plana vitrectomy + irido-zonulo-hyaloidectomy (excision of iris, capsule, zonules, anterior hyaloid) — creates a unicameral eye
- Cyclodiode laser, argon laser of ciliary processes
- Lensectomy with anterior hyaloid disruption
— Wills Eye Manual, pp. 624–625; Kanski's Clinical Ophthalmology, p. 435
Key Points to Remember
| Point | Detail |
|---|---|
| Miotics are CONTRAINDICATED | Pilocarpine worsens aqueous misdirection by contracting the ciliary muscle |
| Atropine is first-line | Reverses ciliolenticular block mechanically |
| Continue atropine indefinitely after resolution | Prevents recurrence |
| Patent PI does NOT rule out malignant glaucoma | Unlike pupillary block, PI does not cure aqueous misdirection |
| B-scan USS is essential | To exclude choroidal detachment before vitrectomy |
This is a shared conversation. Sign in to Orris to start your own chat.